Impact of COVID-19 pandemic on lung cancer treatment scheduling.
Identifieur interne : 000508 ( Main/Exploration ); précédent : 000507; suivant : 000509Impact of COVID-19 pandemic on lung cancer treatment scheduling.
Auteurs : Kohei Fujita [Japon] ; Takanori Ito [Japon] ; Zentaro Saito [Japon] ; Osamu Kanai [Japon] ; Koichi Nakatani [Japon] ; Tadashi Mio [Japon]Source :
- Thoracic cancer [ 1759-7714 ] ; 2020.
Descripteurs français
- KwdFr :
- Anxiété (physiopathologie), Anxiété (psychologie), Betacoronavirus (pathogénicité), Dossiers médicaux (MeSH), Délai jusqu'au traitement (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (physiopathologie), Infections à coronavirus (psychologie), Infections à coronavirus (virologie), Japon (MeSH), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (physiopathologie), Pneumopathie virale (psychologie), Pneumopathie virale (virologie), Poumon (physiopathologie), Poumon (virologie), Protocoles cliniques (MeSH), Recherche sur les services de santé (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Tumeurs du poumon (complications), Tumeurs du poumon (physiopathologie), Tumeurs du poumon (psychologie), Tumeurs du poumon (virologie), Études rétrospectives (MeSH).
- MESH :
- pathogénicité : Betacoronavirus.
- physiopathologie : Anxiété, Infections à coronavirus, Pneumopathie virale, Poumon, Tumeurs du poumon.
- psychologie : Anxiété, Infections à coronavirus, Pneumopathie virale, Tumeurs du poumon.
- virologie : Infections à coronavirus, Pneumopathie virale, Poumon, Tumeurs du poumon.
- Dossiers médicaux, Délai jusqu'au traitement, Femelle, Humains, Infections à coronavirus, Japon, Mâle, Pandémies, Pneumopathie virale, Protocoles cliniques, Recherche sur les services de santé, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du poumon, Études rétrospectives.
- Wicri :
- geographic : Japon.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Anxiety (physiopathology), Anxiety (psychology), Betacoronavirus (pathogenicity), Clinical Protocols (MeSH), Coronavirus Infections (complications), Coronavirus Infections (physiopathology), Coronavirus Infections (psychology), Coronavirus Infections (virology), Female (MeSH), Health Services Research (MeSH), Humans (MeSH), Japan (MeSH), Lung (physiopathology), Lung (virology), Lung Neoplasms (complications), Lung Neoplasms (physiopathology), Lung Neoplasms (psychology), Lung Neoplasms (virology), Male (MeSH), Medical Records (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (physiopathology), Pneumonia, Viral (psychology), Pneumonia, Viral (virology), Retrospective Studies (MeSH), Time-to-Treatment (MeSH).
- MESH :
- geographic : Japan.
- complications : Coronavirus Infections, Lung Neoplasms, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- physiopathology : Anxiety, Coronavirus Infections, Lung, Lung Neoplasms, Pneumonia, Viral.
- psychology : Anxiety, Coronavirus Infections, Lung Neoplasms, Pneumonia, Viral.
- virology : Coronavirus Infections, Lung, Lung Neoplasms, Pneumonia, Viral.
- Aged, Aged, 80 and over, Clinical Protocols, Female, Health Services Research, Humans, Male, Medical Records, Pandemics, Retrospective Studies, Time-to-Treatment.
Abstract
The current coronavirus disease 2019 (COVID-19) pandemic is associated with a heavy burden on the mental and physical health of patients, regional healthcare resources, and global economic activity. Many patients with lung cancer are thought to be affected by this situation. Therefore, in this study, we aimed to evaluate the impact of COVID-19 pandemic on lung cancer treatment scheduling. We retrospectively reviewed the medical records of lung cancer patients who were undergoing anticancer treatment at the National Hospital Organization Kyoto Medical Center (600 beds) in Kyoto, Japan, between 1 March 2020 and 31 May 2020. After the medical records were reviewed, the patients were assigned to one of two groups, depending on whether their lung cancer treatment schedule was delayed. We assessed the characteristics, types of histopathology and treatment, and the reason for the delay. A total 15 (9.1%) patients experienced a delay in lung cancer treatment during the COVID-19 pandemic. Patients with a treatment delay received significantly more immune checkpoint inhibitor (ICI) monotherapy than patients without a treatment delay (P = 0.0057). On the contrary, no patients receiving molecular targeted agents experienced a treatment delay during the COVID-19 pandemic period (P = 0.0027). The treatments of most of the patients were delayed at their request. We determined that 9.1% lung cancer patients suffered anxiety and requested a treatment delay during the COVID-19 pandemic. Oncologists should bear in mind that patients with cancer have more anxiety than expected under unprecedented circumstances such as the COVID-19 pandemic.
DOI: 10.1111/1759-7714.13615
PubMed: 32790028
PubMed Central: PMC7436133
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of COVID-19 pandemic on lung cancer treatment scheduling.</title><author><name sortKey="Fujita, Kohei" sort="Fujita, Kohei" uniqKey="Fujita K" first="Kohei" last="Fujita">Kohei Fujita</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Ito, Takanori" sort="Ito, Takanori" uniqKey="Ito T" first="Takanori" last="Ito">Takanori Ito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Zentaro" sort="Saito, Zentaro" uniqKey="Saito Z" first="Zentaro" last="Saito">Zentaro Saito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Kanai, Osamu" sort="Kanai, Osamu" uniqKey="Kanai O" first="Osamu" last="Kanai">Osamu Kanai</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Nakatani, Koichi" sort="Nakatani, Koichi" uniqKey="Nakatani K" first="Koichi" last="Nakatani">Koichi Nakatani</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Mio, Tadashi" sort="Mio, Tadashi" uniqKey="Mio T" first="Tadashi" last="Mio">Tadashi Mio</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32790028</idno><idno type="pmid">32790028</idno><idno type="doi">10.1111/1759-7714.13615</idno><idno type="pmc">PMC7436133</idno><idno type="wicri:Area/Main/Corpus">000679</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000679</idno><idno type="wicri:Area/Main/Curation">000679</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000679</idno><idno type="wicri:Area/Main/Exploration">000679</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of COVID-19 pandemic on lung cancer treatment scheduling.</title><author><name sortKey="Fujita, Kohei" sort="Fujita, Kohei" uniqKey="Fujita K" first="Kohei" last="Fujita">Kohei Fujita</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Ito, Takanori" sort="Ito, Takanori" uniqKey="Ito T" first="Takanori" last="Ito">Takanori Ito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Zentaro" sort="Saito, Zentaro" uniqKey="Saito Z" first="Zentaro" last="Saito">Zentaro Saito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Kanai, Osamu" sort="Kanai, Osamu" uniqKey="Kanai O" first="Osamu" last="Kanai">Osamu Kanai</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Nakatani, Koichi" sort="Nakatani, Koichi" uniqKey="Nakatani K" first="Koichi" last="Nakatani">Koichi Nakatani</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author><author><name sortKey="Mio, Tadashi" sort="Mio, Tadashi" uniqKey="Mio T" first="Tadashi" last="Mio">Tadashi Mio</name><affiliation wicri:level="1"><nlm:affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation></author></analytic><series><title level="j">Thoracic cancer</title><idno type="eISSN">1759-7714</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Anxiety (physiopathology)</term><term>Anxiety (psychology)</term><term>Betacoronavirus (pathogenicity)</term><term>Clinical Protocols (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (physiopathology)</term><term>Coronavirus Infections (psychology)</term><term>Coronavirus Infections (virology)</term><term>Female (MeSH)</term><term>Health Services Research (MeSH)</term><term>Humans (MeSH)</term><term>Japan (MeSH)</term><term>Lung (physiopathology)</term><term>Lung (virology)</term><term>Lung Neoplasms (complications)</term><term>Lung Neoplasms (physiopathology)</term><term>Lung Neoplasms (psychology)</term><term>Lung Neoplasms (virology)</term><term>Male (MeSH)</term><term>Medical Records (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pneumonia, Viral (psychology)</term><term>Pneumonia, Viral (virology)</term><term>Retrospective Studies (MeSH)</term><term>Time-to-Treatment (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anxiété (physiopathologie)</term><term>Anxiété (psychologie)</term><term>Betacoronavirus (pathogénicité)</term><term>Dossiers médicaux (MeSH)</term><term>Délai jusqu'au traitement (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (physiopathologie)</term><term>Infections à coronavirus (psychologie)</term><term>Infections à coronavirus (virologie)</term><term>Japon (MeSH)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (physiopathologie)</term><term>Pneumopathie virale (psychologie)</term><term>Pneumopathie virale (virologie)</term><term>Poumon (physiopathologie)</term><term>Poumon (virologie)</term><term>Protocoles cliniques (MeSH)</term><term>Recherche sur les services de santé (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Tumeurs du poumon (complications)</term><term>Tumeurs du poumon (physiopathologie)</term><term>Tumeurs du poumon (psychologie)</term><term>Tumeurs du poumon (virologie)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Japan</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Lung Neoplasms</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Anxiété</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Poumon</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Anxiety</term><term>Coronavirus Infections</term><term>Lung</term><term>Lung Neoplasms</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Anxiété</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Anxiety</term><term>Coronavirus Infections</term><term>Lung Neoplasms</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Poumon</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Lung</term><term>Lung Neoplasms</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Clinical Protocols</term><term>Female</term><term>Health Services Research</term><term>Humans</term><term>Male</term><term>Medical Records</term><term>Pandemics</term><term>Retrospective Studies</term><term>Time-to-Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Dossiers médicaux</term><term>Délai jusqu'au traitement</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus</term><term>Japon</term><term>Mâle</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Protocoles cliniques</term><term>Recherche sur les services de santé</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du poumon</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The current coronavirus disease 2019 (COVID-19) pandemic is associated with a heavy burden on the mental and physical health of patients, regional healthcare resources, and global economic activity. Many patients with lung cancer are thought to be affected by this situation. Therefore, in this study, we aimed to evaluate the impact of COVID-19 pandemic on lung cancer treatment scheduling. We retrospectively reviewed the medical records of lung cancer patients who were undergoing anticancer treatment at the National Hospital Organization Kyoto Medical Center (600 beds) in Kyoto, Japan, between 1 March 2020 and 31 May 2020. After the medical records were reviewed, the patients were assigned to one of two groups, depending on whether their lung cancer treatment schedule was delayed. We assessed the characteristics, types of histopathology and treatment, and the reason for the delay. A total 15 (9.1%) patients experienced a delay in lung cancer treatment during the COVID-19 pandemic. Patients with a treatment delay received significantly more immune checkpoint inhibitor (ICI) monotherapy than patients without a treatment delay (P = 0.0057). On the contrary, no patients receiving molecular targeted agents experienced a treatment delay during the COVID-19 pandemic period (P = 0.0027). The treatments of most of the patients were delayed at their request. We determined that 9.1% lung cancer patients suffered anxiety and requested a treatment delay during the COVID-19 pandemic. Oncologists should bear in mind that patients with cancer have more anxiety than expected under unprecedented circumstances such as the COVID-19 pandemic.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32790028</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-7714</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Thoracic cancer</Title><ISOAbbreviation>Thorac Cancer</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 pandemic on lung cancer treatment scheduling.</ArticleTitle><Pagination><MedlinePgn>2983-2986</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.13615</ELocationID><Abstract><AbstractText>The current coronavirus disease 2019 (COVID-19) pandemic is associated with a heavy burden on the mental and physical health of patients, regional healthcare resources, and global economic activity. Many patients with lung cancer are thought to be affected by this situation. Therefore, in this study, we aimed to evaluate the impact of COVID-19 pandemic on lung cancer treatment scheduling. We retrospectively reviewed the medical records of lung cancer patients who were undergoing anticancer treatment at the National Hospital Organization Kyoto Medical Center (600 beds) in Kyoto, Japan, between 1 March 2020 and 31 May 2020. After the medical records were reviewed, the patients were assigned to one of two groups, depending on whether their lung cancer treatment schedule was delayed. We assessed the characteristics, types of histopathology and treatment, and the reason for the delay. A total 15 (9.1%) patients experienced a delay in lung cancer treatment during the COVID-19 pandemic. Patients with a treatment delay received significantly more immune checkpoint inhibitor (ICI) monotherapy than patients without a treatment delay (P = 0.0057). On the contrary, no patients receiving molecular targeted agents experienced a treatment delay during the COVID-19 pandemic period (P = 0.0027). The treatments of most of the patients were delayed at their request. We determined that 9.1% lung cancer patients suffered anxiety and requested a treatment delay during the COVID-19 pandemic. Oncologists should bear in mind that patients with cancer have more anxiety than expected under unprecedented circumstances such as the COVID-19 pandemic.</AbstractText><CopyrightInformation>© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6902-9085</Identifier><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Zentaro</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanai</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-0736-3317</Identifier><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatani</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mio</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Thorac Cancer</MedlineTA><NlmUniqueID>101531441</NlmUniqueID><ISSNLinking>1759-7706</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">lung cancer</Keyword><Keyword MajorTopicYN="Y">pandemic</Keyword><Keyword MajorTopicYN="Y">treatment delay</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32790028</ArticleId><ArticleId IdType="doi">10.1111/1759-7714.13615</ArticleId><ArticleId IdType="pmc">PMC7436133</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19) situation reports. 2020. [Cited 23 Jul 2020.] Available from URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.</Citation></Reference><Reference><Citation>Johns Hopkins University and Medicine. Coronavirus Resource Center. 2020. [Cited 23 Jul 2020.] Available from URL: https://coronavirus.jhu.edu/map.html. Accessed at July 23, 2020.</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare of Japan. Coronavirus Diseases (COVID-19) situation. 2020. [Cited 23 Jul 2020.] Available from URL: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/newpage_00032.html.</Citation></Reference><Reference><Citation>Tian J, Yuan X, Xiao J et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893-903.</Citation></Reference><Reference><Citation>Liang W, Guan W, Chen R e a. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21: 335-7.</Citation></Reference><Reference><Citation>Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020; 6: 1108.</Citation></Reference><Reference><Citation>Ouyang W, Hu J, Zhang H, Xie C. The management of patients with lung cancer during the outbreak of coronavirus disease 2019. J Thorac Oncol 2020; 15: e106-7.</Citation></Reference><Reference><Citation>Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D, International Oncology Panel and European Cancer Patient Coalition Collaborators. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. Lancet Oncol 2020; 21: 759-60.</Citation></Reference><Reference><Citation>Goldstein DA, Ratain MJ, Saltz LB. Weight-based dosing of pembrolizumab every 6 weeks in the time of COVID-19. JAMA Oncol 2020 May 27. https://doi.org/10.1001/jamaoncol.2020.2493 [Epub ahead of print].</Citation></Reference><Reference><Citation>Robilotti EV, Babady NE, Mead PA et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020 Jun 24. https://doi.org/10.1038/s41591-020-0979-0 [Epub ahead of print].</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Fujita, Kohei" sort="Fujita, Kohei" uniqKey="Fujita K" first="Kohei" last="Fujita">Kohei Fujita</name></noRegion><name sortKey="Ito, Takanori" sort="Ito, Takanori" uniqKey="Ito T" first="Takanori" last="Ito">Takanori Ito</name><name sortKey="Kanai, Osamu" sort="Kanai, Osamu" uniqKey="Kanai O" first="Osamu" last="Kanai">Osamu Kanai</name><name sortKey="Mio, Tadashi" sort="Mio, Tadashi" uniqKey="Mio T" first="Tadashi" last="Mio">Tadashi Mio</name><name sortKey="Nakatani, Koichi" sort="Nakatani, Koichi" uniqKey="Nakatani K" first="Koichi" last="Nakatani">Koichi Nakatani</name><name sortKey="Saito, Zentaro" sort="Saito, Zentaro" uniqKey="Saito Z" first="Zentaro" last="Saito">Zentaro Saito</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000508 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000508 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32790028
|texte= Impact of COVID-19 pandemic on lung cancer treatment scheduling.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32790028" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |